CML-paed II Register

Pediatric oncology/hematology
Leukemias
Register and supportive Studies
Patients are usually diagnosed and treated at the GPOH centres (see list) in accordance with the guidelines. Treatment is carried out within the scope of the authorisation with imatinib as well as with the now approved second-generation tyrosine kinase inhibitors, dasatinib and nilotinib. The drugs are not given on a trial basis. The patients are treated independently of the registry (before and after). There are also no disadvantages for current and future therapies as a result of the registry. Since 01.01.2016, the registry has also served to continue a therapy optimisation study closed on 31.12.2015 (follow-up completed at the end of 2020), initially based in Dresden, since the change of study management from 01.04.2018 based in Erlangen. Study arms: None